Keyphrases
Activity in Vivo
16%
Alveolar Bone Destruction
16%
Alveolar Bone Resorption
100%
Anti-inflammatory Properties
16%
Anti-inflammatory Response
16%
Bacterial Antigens
16%
Cell Signaling Pathways
16%
Cytokine Production
100%
Endotoxin Level
50%
Escherichia Coli
16%
Gene Transcription
33%
Gingiva
33%
IL-1R
16%
Inflammasome
33%
Inflammatory Cytokine Response
16%
Inflammatory Cytokines
100%
Inflammatory Diseases
16%
Interleukin-1β
16%
Interleukin-6
33%
Ligature-induced Periodontitis
16%
Lipopolysaccharide
100%
Macrophages
16%
Murine Macrophages
16%
Nuclear factor-B
16%
Oral Administration
33%
Oral Cavity
33%
Periodontal Inflammation
16%
Periodontitis
33%
Periodontitis Model
50%
Porphyromonas Gingivalis (P. gingivalis)
16%
Preventive Effect
16%
Recombinant
16%
Rice
100%
Signaling Cascades
16%
Suppression Effect
16%
Medicine and Dentistry
Alternative Complement Pathway C3 C5 Convertase
16%
Alveolar Bone
16%
Alveolar Bone Resorption
100%
Anti-Inflammatory Drug
33%
Bacterial Antigen
16%
Bone Destruction
16%
Cell Signaling Pathway
16%
Cytokine
16%
Cytokine Production
100%
Endotoxin
50%
Escherichia coli
16%
Genetic Transcription
33%
Gum (Oral Cavity)
33%
In Vitro
16%
Inflammasome
33%
Inflammatory Cytokine
100%
Inflammatory Disorder
16%
Interleukin 6
16%
Interleukin-1
16%
Interleukin-6
16%
Lipopolysaccharide
100%
Macrophage
33%
Neutralization
16%
Nuclear Factor
16%
Oral Cavity
33%
Oral Drug Administration
33%
Periodontitis
83%
Porphyromonas gingivalis
16%
Serositis
16%
Immunology and Microbiology
Alveolar Bone
100%
Bacterial Antigen
20%
Complement Factor B
20%
Cytokine Production
100%
Escherichia coli
20%
Experimental Model
20%
Genetic Transcription
40%
Gingiva
40%
Inflammasome
40%
Inflammation Response
20%
Inflammatory Cytokine
100%
Inflammatory Disorder
20%
Interleukin 6
20%
Interleukin-1
20%
Interleukin-6
20%
Macrophage
40%
Mouse
40%
Neutralization
20%
Osteolysis
100%
Periodontitis
100%
Porphyromonas gingivalis
20%
Proinflammatory Cytokine
40%
Signal Transduction
40%
Pharmacology, Toxicology and Pharmaceutical Science
Alternative Complement Pathway C3 C5 Convertase
16%
Anti-Inflammatory Drug
33%
Bacterial Antigen
16%
Bone Destruction
16%
Cytokine
100%
Endotoxin
50%
Escherichia coli
16%
Inflammasome
33%
Inflammation
33%
Inflammatory Disease
16%
Interleukin 6
16%
Lipopolysaccharide
100%
Mouse
33%
Nuclear Factor
16%
Periodontitis
83%
Porphyromonas gingivalis
16%